Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05613062

Modified Huang-Lian-Jie-Du Decoction (MHLJDD) for Atopic Dermatitis in Children

Conditions: Atopic Dermatitis

Sex: All
Ages: 4 Years – 17 Years
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 20
Sponsor: Chinese University of Hong Kong

Location: School of Chinese Medicine Hong Kong

Summary

The study aims to evaluate the clinical efficacy of Chinese medicine (CM) for the treatment of subacute and chronic Atopic Dermatitis (AD) patients when compared to the placebo control by examining the clinical symptoms.

Eligibility Criteria

Inclusion Criteria: * Age of 4 to 17 (Chinese only); * With EASI ≥ 10; * Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematous papules and plaques; and * Provide a written informed consent form (signed by one of their parents) Exclusion Criteria: * History of allergy to Chinese medicines; * AD with Yang deficiency in syndrome differentiation, such as pale looking, always feeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such as urinary difficulty, excessive urination or incontinence * Known overt bacterial infections in the skin; * Known pregnancy; * Known severe medical conditions, such as cardiovascular, liver or renal dysfunction or Diabetes Mellitus; * Having used oral corticosteroids, oral antibiotics, other immunosuppressive or any preparation of oral herbal medicines for the treatment of AD in the past month; * Having been diagnosed with scabies, allergic contact dermatitis, seborrheic dermatitis or psoriasis; * Has taken anti-coagulant or anti-platelet drugs in the past month; * Has taken any probiotics, prebiotics in the last month; and * Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05613062). StuddyBuddy aggregates publicly available trial information.